• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kimball Electronics, Inc. Announces Appointment of Additional Director

    9/15/22 4:05:00 PM ET
    $BHC
    $KE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Technology
    Get the next $BHC alert in real time by email

    Kimball Electronics, Inc. (NASDAQ:KE), announces the expansion of its Board of Directors and appointment of a new director at its regularly scheduled Board Meeting on September 13, 2022.

    Tom Vadaketh was selected to the Company's Board of Directors (the "Board"), effective as of the September meeting. Mr. Vadaketh will serve on the Audit Committee and will stand for election to a full term at the 2022 Annual Meeting of Share Owners in November.

    Mr. Vadaketh serves as Chief Financial Officer of Bausch Health (NYSE:BHC) (TSX:BHC), which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices globally, primarily in the therapeutic areas of eye-health, gastroenterology, and dermatology.

    Prior to joining Bausch Health in January 2022, Mr. Vadaketh served as Executive Vice President and Chief Financial Officer of eResearch Technology, Inc. from September 2018 to December 2021, where he was responsible for leading the Finance function including controllership, treasury, taxation, and financial planning.

    Prior to that, he was Executive Vice President and Chief Financial Officer of Cambrex Corporation. In addition, Mr. Vadaketh spent over 20 years at Procter & Gamble and Tyco International, where he held several roles of increasing responsibility at both companies.

    Mr. Vadaketh received a degree from the Institute of Chartered Accountants in England and Wales (ACA) and an M.B.A. from Manchester Business School. He is a Certified Public Accountant.

    "Speaking on behalf of our Board, it is an honor to have Tom join us with his well-rounded financial expertise, vast experience with major multinational organizations, and demonstrated leadership in a variety of global businesses driving both organic growth and strategic acquisitions," said Don Charron, Chairman of the Board and Chief Executive Officer. "Tom further enhances our Board's distinct and valuable skill sets as we continue to build lasting relationships and global success with our stakeholders. We expect to learn a lot from Tom so that we become an even better company while creating quality for life."

    About Kimball Electronics, Inc.

    Kimball Electronics is a multifaceted manufacturing solutions provider of electronics and diversified contract manufacturing services to customers around the world. From our operations in the United States, China, India, Japan, Mexico, Poland, Romania, Thailand, and Vietnam, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (NASDAQ:KE) is headquartered in Jasper, Indiana.

    To learn more about Kimball Electronics, visit: www.kimballelectronics.com.

    Lasting relationships. Global success.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005963/en/

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC
    $KE

    CompanyDatePrice TargetRatingAnalyst
    Bausch Health Companies Inc.
    $BHC
    12/9/2025$8.00Equal Weight
    Barclays
    Kimball Electronics Inc.
    $KE
    8/15/2024Buy → Neutral
    Sidoti
    Bausch Health Companies Inc.
    $BHC
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    Bausch Health Companies Inc.
    $BHC
    7/10/2024$8.00Mkt Perform
    Raymond James
    Kimball Electronics Inc.
    $KE
    10/9/2023$39.00Buy
    B. Riley Securities
    Bausch Health Companies Inc.
    $BHC
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    Bausch Health Companies Inc.
    $BHC
    6/16/2023Outperform → Market Perform
    TD Cowen
    Kimball Electronics Inc.
    $KE
    6/15/2023$3.40Overweight
    Cantor Fitzgerald
    More analyst ratings

    $BHC
    $KE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

    Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes

    5/28/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics to Participate at the 26th Annual B. Riley Securities Institutional Investor Conference

    Kimball Electronics, Inc. (NASDAQ:KE) today announced the Company will be attending the 26th Annual B. Riley Securities Institutional Investor Conference, which is being held May 20-21 at the Ritz Carlton Marina Del Rey, CA. Jana Croom, Chief Financial Officer, and Andrew Regrut, Vice President, Investor Relations, Strategic Development, and Treasurer, will be available for one-on-one meetings throughout the conference. For additional information about the conference or to schedule a one-on-one meeting with Kimball Electronics management, please contact your B. Riley Securities representative or the Company's investor relations team at Investor.Relations@kimballelectronics.com or KE@gatew

    5/19/26 4:05:00 PM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics downgraded by Sidoti

    Sidoti downgraded Kimball Electronics from Buy to Neutral

    8/15/24 7:57:54 AM ET
    $KE
    Electrical Products
    Technology

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Director Phillips Richard D received a gift of 4,214 shares and gifted 4,214 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Kimball Electronics, Inc. (0001606757) (Issuer)

    6/3/26 2:48:27 PM ET
    $KE
    Electrical Products
    Technology

    VP IR & Strategy, Treasurer Regrut Andrew Donald converted options into 1,052 shares and covered exercise/tax liability with 457 shares, increasing direct ownership by 12% to 5,379 units (SEC Form 4) to satisfy withholding obligation

    4 - Kimball Electronics, Inc. (0001606757) (Issuer)

    6/3/26 2:30:39 PM ET
    $KE
    Electrical Products
    Technology

    CEO and Director Phillips Richard D gifted 77,974 shares and received a gift of 77,974 shares, decreasing direct ownership by 95% to 4,214 units (SEC Form 4)

    4 - Kimball Electronics, Inc. (0001606757) (Issuer)

    5/28/26 8:43:02 AM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    SEC Filings

    View All

    SEC Form SD filed by Bausch Health Companies Inc.

    SD - Bausch Health Companies Inc. (0000885590) (Filer)

    6/1/26 4:06:14 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Kimball Electronics Inc.

    SD - Kimball Electronics, Inc. (0001606757) (Filer)

    5/20/26 3:17:08 PM ET
    $KE
    Electrical Products
    Technology

    Bausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    5/19/26 4:18:10 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics Intensifies Focus on Strategic Development With Appointment of a New Member to Its Leadership Team; Company to Participate at the Piper Sandler 37th Annual Healthcare Conference

      Kimball Electronics, Inc. (NASDAQ:KE) today announced the Company is intensifying its focus on strategic development with the appointment of a new member to its leadership team. Andrew D. Regrut, Treasurer and Investor Relations Officer, will now also lead the strategic development efforts of the Company. Commenting on Mr. Regrut's expanded role, Jana T. Croom, Chief Financial Officer, stated, "I'm thrilled to be announcing Andy's promotion and addition to our leadership team. He has been instrumental in our recent efforts to optimize debt levels through improved working capital management and global cash movement. We look for his energy and intensity to elevate our focus on strategic d

    12/2/25 8:30:00 AM ET
    $KE
    Electrical Products
    Technology

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Financials

    Live finance-specific insights

    View All

    Kimball Electronics Reports Q3 Results With Double-Digit Sequential Medical Sales Growth; Company Affirms Guidance for Fiscal 2026 With Adjusted Operating Margin Expected at High End of Range

    Third Quarter 2026 Highlights Revenue of $352.9 million, a sequential increase of 3.4% compared to Q2 Sales in the medical vertical increased 10.2% versus the prior quarter Operating income of $11.8 million, or 3.3% of net sales, adjusted operating margin of 4.2% Cash from operations of $14.9 million, the ninth consecutive quarter of positive operating cash generation Debt of $163.0 million and borrowing capacity of $276.0 million Cash Conversion Days of 90, an improvement compared to both the prior quarter and Q3 of fiscal 2025 Invested $4.0 million to repurchase 165,000 shares of common stock Company affirms guidance for fiscal 2026 with adjusted operating margin e

    5/5/26 4:05:00 PM ET
    $KE
    Electrical Products
    Technology

    BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

    First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q

    4/29/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics, Inc. Announces Date For Reporting Third Quarter Fiscal Year 2026 Financial Results

    Kimball Electronics, Inc. (NASDAQ:KE) today announced that it will report third quarter fiscal year 2026 financial results on Tuesday, May 5, 2026, after the closing of the market. The company will host a conference call and live webcast to review the results on Wednesday, May 6, 2026, at 10:00 a.m. Eastern Time. The telephone number to access the conference call is 877-407-8293 / +1 201-689-8349. A live webcast of the conference call can be accessed at investors.kimballelectronics.com. For those unable to participate in the live webcast, a replay will be archived at investors.kimballelectronics.com. About Kimball Electronics, Inc. Kimball Electronics is a global, multifaceted ma

    4/22/26 9:41:00 AM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

    SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    11/12/24 3:47:56 PM ET
    $KE
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

    SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    11/4/24 11:46:47 AM ET
    $KE
    Electrical Products
    Technology

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care